W.G. Shaheen & Associates Dba Whitney & CO Bristol Myers Squibb CO Transaction History

W.G. Shaheen & Associates Dba Whitney & CO

$915 Million
Q3 2024

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 03, 2023	BUY	$65.71 - $74.53 $985 - $1,117	15 Added 0.5%	2,991 $207,000
Q4 2022 Feb 03, 2023	BUY	$68.48 - $81.09 $890 - $1,054	13 Added 0.44%	2,976 $214,000
Q3 2022 Nov 09, 2022	BUY	$0.13 - $76.84 $8 - $4,917	64 Added 2.21%	2,963 $211,000
Q2 2022 Aug 05, 2022	BUY	$72.62 - $79.98 $944 - $1,039	13 Added 0.45%	2,899 $223,000
Q1 2022 May 13, 2022	BUY	$61.48 - $73.72 $177,431 - $212,755	2,886 New	2,886 $211,000
Q3 2021 Nov 12, 2021	SELL	$59.17 - $69.31 $185,852 - $217,702	-3,141 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$61.91 - $67.42 $194,459 - $211,766	3,141 New	3,141 $210,000
Q1 2021 May 11, 2021	SELL	$59.34 - $66.74 $184,725 - $207,761	-3,113 Closed	0 $0
Q4 2020 Feb 10, 2021	BUY	$57.74 - $65.43 $179,744 - $203,683	3,113 New	3,113 $201,000
Q4 2018 Feb 07, 2019	SELL	$48.76 - $63.23 $78,016 - $101,168	-1,600 Closed	0 $0
Q1 2018 May 11, 2018	BUY	$59.92 - $68.98 $95,872 - $110,368	1,600 New	1,600 $101,000

Others Institutions Holding BMY

# of Institutions

2,536

Shares Held

1.47B

Call Options Held

31.6M

Put Options Held

35M

Vanguard Group Inc Valley Forge, PA

189M
Shares

$10.9 Billion
0.18% of portfolio
Black Rock Inc. New York, NY

159M
Shares

$9.15 Billion
0.15% of portfolio
State Street Corp Boston, MA

92.9M
Shares

$5.36 Billion
0.2% of portfolio
Jpmorgan Chase & CO New York, NY

77.9M
Shares

$4.5 Billion
0.33% of portfolio
Charles Schwab Investment Management Inc San Francisco, CA

61M
Shares

$3.52 Billion
0.61% of portfolio

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $123B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of W.G. Shaheen & Associates Dba Whitney & CO, based on Form 13F filings with the SEC.

News

Stay updated on W.G. Shaheen & Associates Dba Whitney & CO with notifications on news.

Account